Le point sur les signatures moléculaires dans le cancer du sein

作者: F. Reyal , J. -Y. Pierga , R. -J. Salmon , A. Vincent-Salomon , M. -A. Bollet

DOI: 10.1007/S10269-010-1876-9

关键词:

摘要: Les criteres usuels cliniques et pathologiques ne permettent pas de definir precisement le pronostic individuel des patientes traitees pour cancer du sein entrainent un « surtraitement » adjuvant d’un grand nombre d’entre elles. Trois outils fondes sur l’expression genique, a moyen ou haut debit, ont ete developpes tenter pallier cette imprecision. Leurs validations series independantes abouti leur developpement commercial. etudes sont en cours savoir dans quelle mesure ces signatures genomiques apportent benefice cliniquement perceptible termes meilleure indication therapeutique. Ces moleculaires premiere generation reposent essentiellement composition les voies recepteurs aux estrogenes, gene HER2 la proliferation. Il reste demontrer qu’une utilisation marqueurs immunohistochimiques routine, correctement calibres combines n’apporte une information equivalente.

参考文章(33)
Kathy D. Miller, G. Thomas Budd, Eleftherios P. Mamounas, Incorporating the Oncotype DX breast cancer assay into community practice: an expert Q&A and case study sampling. Clinical advances in hematology & oncology. ,vol. 6, pp. 1- 8 ,(2008)
Laurel A Habel, Steven Shak, Marlena K Jacobs, Angela Capra, Claire Alexander, Mylan Pho, Joffre Baker, Michael Walker, Drew Watson, James Hackett, Noelle T Blick, Deborah Greenberg, Louis Fehrenbacher, Bryan Langholz, Charles P Quesenberry, A population-based study of tumor gene expression and risk of breast cancer death among lymph node-negative patients Breast Cancer Research. ,vol. 8, pp. 1- 15 ,(2006) , 10.1186/BCR1412
M. Schena, D. Shalon, R. W. Davis, P. O. Brown, Quantitative Monitoring of Gene Expression Patterns with a Complementary DNA Microarray Science. ,vol. 270, pp. 467- 470 ,(1995) , 10.1126/SCIENCE.270.5235.467
Daniela Dunkler, Stefan Michiels, Michael Schemper, Gene expression profiling: Does it add predictive accuracy to clinical characteristics in cancer prognosis? European Journal of Cancer. ,vol. 43, pp. 745- 751 ,(2007) , 10.1016/J.EJCA.2006.11.018
Ido Wolf, Noa Ben-Baruch, Ronnie Shapira-Frommer, Shulamit Rizel, Hadassa Goldberg, Neora Yaal-Hahoshen, Baruch Klein, David B. Geffen, Bella Kaufman, Association between standard clinical and pathologic characteristics and the 21-gene recurrence score in breast cancer patients: a population-based study. Cancer. ,vol. 112, pp. 731- 736 ,(2008) , 10.1002/CNCR.23225
Mark Schena, Renu A Heller, Thomas P Theriault, Ken Konrad, Eric Lachenmeier, Ronald W Davis, Microarrays: biotechnology's discovery platform for functional genomics Trends in Biotechnology. ,vol. 16, pp. 301- 306 ,(1998) , 10.1016/S0167-7799(98)01219-0
Christopher W Elston, Ian O Ellis, Sarah E Pinder, Pathological prognostic factors in breast cancer. Critical Reviews in Oncology Hematology. ,vol. 31, pp. 209- 223 ,(1999) , 10.1016/S1040-8428(99)00034-7